|
RTN3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
3.51779999999691E-05 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
8.096700E-03 |
| Stage1-vs-Stage3 |
1.683970E-02 |
| Stage1-vs-Stage4 |
2.43309999999886E-05 |
| Stage2-vs-Stage3 |
5.188600E-04 |
| Stage2-vs-Stage4 |
4.06279999998205E-06 |
| Stage3-vs-Stage4 |
8.686400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.72909999984761E-07 |
| Normal-vs-Asian |
1.63002944475465E-12 |
| Caucasian-vs-AfricanAmerican |
4.119800E-01 |
| Caucasian-vs-Asian |
7.311800E-01 |
| AfricanAmerican-vs-Asian |
5.910800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.10782519111308E-15 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
9.861200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62736490949555E-12 |
| Normal-vs-Age(81-100Yrs) |
4.26980000023391E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.803400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.775000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.003210E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.839800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.461020E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.524570E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.11359999963734E-07 |
| Classical-VS-Follicular |
8.48350000248743E-08 |
| Classical-VS-Other |
6.265800E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.64801505775358E-12 |
| Tall-VS-Other |
5.704200E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
6.608400E-04 |
| Follicular-VS-Normal |
4.21550000000437E-05 |
| Other-VS-Normal |
1.52609999970466E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.63877808492907E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
2.45429998546598E-09 |
|
|
